Eli Lilly and Company STOCK OVERVIEW

SNAPSHOT

Ticker	LLY	Market Cap	$992.4B
Sector	Biopharmaceuticals	P/E	46.57
52 Week High-Low	$623.78-$1133.95	3 Year Beta	0.7
CEO	David A. Ricks, MBA	Target Price	$1243.87

BUSINESS MODEL

Products

Eli Lilly discovers, develops, manufactures, and markets branded human pharmaceutical products across four primary therapeutic areas: cardiometabolic health, oncology, immunology, and neuroscience. Its portfolio includes incretin-based therapies such as Mounjaro and Zepbound for diabetes and obesity, insulin products including Humalog and Humulin, oncology medicines such as Verzenio, Retevmo, and Jaypirca, immunology treatments including Taltz and Omvoh, and neuroscience therapies such as Emgality and Kisunla. The company’s products are protected by patents, biologics exclusivity, and regulatory data protection frameworks, with revenue driven primarily by innovative, patent-protected medicines sold globally.

Customer Base

Lilly serves a global healthcare market spanning approximately 90 countries. Its primary customers include pharmaceutical wholesalers, pharmacy benefit managers, managed care organizations, government healthcare programs (including Medicare and Medicaid), hospitals, long-term care institutions, and retail pharmacies. Outside the United States, national health systems and state-owned hospitals represent significant purchasers. In the U.S., a substantial portion of product distribution flows through three major wholesale distributors, which account for a meaningful share of consolidated revenue. Healthcare providers, physicians, and endocrinology and oncology specialists represent key prescriber segments across major therapeutic areas.

Pricing Method

Pricing is influenced by therapeutic value, clinical differentiation, competitive dynamics, and regulatory frameworks. In the United States, list prices are subject to negotiated rebates and discounts with pharmacy benefit managers, private insurers, and government programs. Net realized pricing is materially affected by Medicaid rebates, 340B program pricing, Medicare Part D redesign provisions, and Inflation Reduction Act price-setting mechanisms for certain mature products. Outside the U.S., pricing is often determined through government negotiations, reference pricing systems, health technology assessments, and mandatory rebates. In markets such as China and parts of Europe, inclusion on national reimbursement lists typically requires significant price concessions in exchange for broader patient access.

Supply Chain

Lilly operates a global manufacturing and distribution network with production facilities in the United States (including Puerto Rico), Europe, and Asia. The company manufactures finished dosage forms, biologics, and active pharmaceutical ingredients internally and through select third-party manufacturing partners, subject to strict regulatory oversight and current Good Manufacturing Practice (cGMP) standards. The supply chain includes sourcing of raw materials, biologic production capacity expansion, cold-chain logistics for certain therapies, and coordination with wholesale distributors and healthcare systems. Given high demand for incretin-based therapies, capacity expansion and supply reliability represent strategic operational priorities.

Sales Channels

Products are commercialized through a combination of direct sales representatives, account managers, digital platforms, and third-party partnerships. In the United States, Lilly promotes products directly to healthcare providers and, for certain therapies, through direct-to-consumer advertising. The company also operates LillyDirect, a direct-to-patient digital platform that facilitates access and fulfillment through third-party pharmacies. Outside the U.S., Lilly utilizes its own sales organizations and distribution partners to market products to healthcare providers and government systems. Collaborative arrangements with other pharmaceutical companies support commercialization of select products in specific geographies.

INDUSTRY ANALYSIS: PORTER'S 5 FORCES

Threat of New Entrants — Low

The branded pharmaceutical industry is characterized by exceptionally high barriers to entry driven by regulatory complexity, capital intensity, scientific risk, and intellectual property protection. Developing a novel therapeutic requires extensive preclinical research, multi-phase clinical trials, regulatory approval processes across multiple jurisdictions, and substantial manufacturing validation under strict current Good Manufacturing Practice standards. Patent protection, biologics data exclusivity, and regulatory data protection frameworks further limit immediate competition following approval. Established relationships with regulators, payers, healthcare providers, and global distribution networks reinforce incumbent advantages. While biotechnology startups can enter specific therapeutic niches, replicating Lilly’s scale, global commercial infrastructure, and diversified late-stage pipeline presents a significant structural barrier.

Bargaining Power of Buyers — High

Buyers in pharmaceuticals include large wholesale distributors, pharmacy benefit managers (PBMs), managed care organizations, government healthcare programs, and national health systems, all of which exercise meaningful pricing leverage. In the United States, Medicare, Medicaid, and the 340B program impose statutory rebates and pricing constraints, while the Inflation Reduction Act introduces government-set pricing for certain mature therapies. PBMs and insurers negotiate rebates in exchange for formulary placement, and unfavorable positioning can materially reduce volume. Outside the U.S., single-payer systems and health technology assessments often require significant price concessions for reimbursement inclusion. Although Lilly’s clinically differentiated therapies—particularly in cardiometabolic and oncology markets—provide some negotiating leverage, consolidated payer power structurally elevates buyer influence over net pricing.

Bargaining Power of Suppliers — Moderate

Lilly maintains a vertically integrated manufacturing network but depends on specialized suppliers for active pharmaceutical ingredients, biologic materials, device components, packaging, and certain third-party manufacturing services. Biologics production, cold-chain logistics, and advanced injectable device manufacturing require specialized capabilities that may be concentrated among limited vendors. Regulatory requirements restrict rapid supplier substitution, increasing switching costs in certain categories. However, Lilly’s scale, diversified supplier base, and internal manufacturing footprint mitigate extreme dependency. While supplier disruptions can impact short-term output—particularly for high-demand incretin therapies—supplier power is generally balanced by Lilly’s purchasing scale and long-term contractual arrangements.

Threat of Substitutes - Moderate to High

Substitution risk in pharmaceuticals arises primarily from generic drugs, biosimilars, alternative branded therapies, and emerging treatment modalities. Upon patent expiration, small-molecule products typically face rapid generic erosion, often resulting in steep price and volume declines. Biologic therapies face increasing biosimilar competition as regulatory pathways mature globally. Additionally, alternative drug classes, new mechanisms of action, lifestyle interventions, and medical devices can compete for similar patient populations. In obesity and diabetes, competing GLP-1–based and next-generation metabolic therapies intensify substitution dynamics. However, strong clinical efficacy, safety profiles, and brand trust can delay displacement during exclusivity periods.

 Competitive Rivalry — High

Lilly competes in intensely competitive global pharmaceutical markets characterized by rapid innovation, large-scale R&D investment, and significant marketing expenditures. Rivalry is particularly strong in cardiometabolic health, oncology, and immunology, where multiple multinational pharmaceutical companies pursue overlapping indications and pipeline expansions. Competition occurs across clinical differentiation, safety profiles, pricing negotiations, speed of regulatory approval, and payer access. Patent litigation, biosimilar challenges, and health policy developments further heighten competitive intensity. Sustained rivalry is reinforced by high fixed R&D costs, product concentration risk, and the need for continuous pipeline replenishment to offset patent expirations.

VALUATION: DISCOUNTED CASH FLOW

WACC

INVESTMENT RISKS

Systematic Risk

Market Risk: Lilly exhibits below-market volatility, reflected in its 3-year adjusted Beta of 0.70, indicating lower sensitivity to broad equity market movements relative to the S&P 500. However, valuation multiples remain elevated for a defensive healthcare company, with a P/E (LTM) of 46.57, EV/EBITDA of 32.39, and EV/Sales of 15.75. These levels imply significant growth expectations embedded in the current price.

At a market capitalization of approximately $992 billion and an enterprise value exceeding $1.02 trillion, Lilly trades at premium multiples relative to historical pharmaceutical averages. In an environment of rising interest rates, tightening liquidity, or sector-wide multiple compression in growth healthcare equities, valuation contraction risk remains meaningful. While Beta suggests lower volatility, multiple compression could still materially impact share price due to elevated expectations around obesity and incretin-driven growth.

Geopolitical Risk: Geopolitical risk for Eli Lilly is moderate and primarily tied to global regulatory exposure, international pricing negotiations, and supply chain concentration. A meaningful portion of revenue is generated outside the United States, exposing the company to foreign currency fluctuations, trade policy shifts, and government-controlled healthcare reimbursement systems. Many international markets operate under single-payer or price-controlled frameworks, where political decisions can directly impact drug pricing and market access. In addition, cross-border manufacturing and sourcing of active pharmaceutical ingredients create vulnerability to trade restrictions, export controls, or regional instability. While pharmaceuticals are generally less cyclical than industrial sectors, increasing political scrutiny of drug pricing and healthcare spending globally represents a structural geopolitical overhang for long-duration growth expectations.

Unsystematic Risk

Business Risk: Revenue growth expectations are substantial, reflected in premium valuation metrics. Consensus revenue of approximately $17.6 billion next quarter and EPS expectations of $7.33 indicate continued strong operating performance. However, the P/S multiple of 15.25 suggests the market is pricing in durable, high-margin expansion from incretin therapies (Mounjaro/Zepbound).

Product concentration risk is elevated. A significant portion of incremental growth is tied to obesity and diabetes franchises. Competitive GLP-1 and next-generation metabolic therapies introduce competitive and pricing risk. Additionally, payer negotiations, formulary positioning, and government pricing reforms (particularly in the U.S.) could pressure net realized pricing over time.

Financial Risk: The company’s Enterprise Value of approximately $1.64 trillion relative to its market capitalization reflects meaningful debt within the capital structure. While operating performance has supported strong margins, an EV/EBITDA multiple near 47x suggests the market is discounting sustained high EBITDA growth. If EBITDA growth moderates or AI infrastructure investment slows, leverage metrics could deteriorate relative to expectations. Additionally, acquisition driven expansion historically increases balance sheet risk if funded through incremental debt.

Liquidity Risk: The enterprise value of approximately $1.026 trillion compared to a market capitalization of $992 billion indicates manageable net debt rather than an aggressively levered balance sheet. The EV/EBITDA multiple of 32.39x implies strong underlying EBITDA generation relative to total firm value, supporting debt servicing capacity. Although the annual dividend of $6.92 represents a recurring cash obligation, the capital structure reflected in the EV-to-equity relationship does not suggest near-term balance sheet stress. Based on these ratios, corporate liquidity appears stable under current operating conditions.

Regulatory Risk: Pharmaceutical pricing remains under significant regulatory scrutiny. U.S. government price-setting mechanisms and global reimbursement negotiations create structural pricing pressure. High-margin products with strong sales trajectories are more likely to be targeted under price reform initiatives. Given Lilly’s scale and visibility, future inclusion of major products in price negotiation frameworks could accelerate revenue deceleration relative to patent expiry timelines.

MANAGEMENT

David A. Ricks, MBA

Chairman, President & Chief Executive Officer

David has been with Eli Lilly since 1996 and has served as Chairman and Chief Executive Officer since 2017. He previously held leadership roles including President of Lilly USA, General Manager of Lilly Canada, and President and General Manager of Lilly China. Earlier in his career, he held executive positions across multiple global markets within the company. He serves on several corporate and industry boards and holds an MBA from Indiana University and an undergraduate degree from Purdue University.

__________________________________________________________________________________

Lucas E. Montarce, MBA

Chief Financial Officer & Executive Vice President

Lucas has been with Eli Lilly since 2001 and has served as Chief Financial Officer since 2024. He previously held senior finance leadership roles including Controller and Chief Financial Officer of Lilly Research Laboratories, as well as CFO of Elanco Animal Health. Prior to his current role, he held various global finance positions within the organization. He holds an undergraduate degree from The Catholic University of America and a master’s degree in business administration from Universidad del CEMA.

__________________________________________________________________________________

David Hyman, MD

Chief Medical Officer

David joined Eli Lilly in 2023 as Chief Medical Officer. He also serves as Chief Medical Officer of Loxo Oncology, a subsidiary of Lilly. Prior to joining the company, he held senior oncology leadership roles in clinical development and translational medicine. He earned his medical degree and has built his career specializing in oncology research and drug development.

__________________________________________________________________________________

Diogo Rau

Executive Vice President, Chief Information & Digital Officer

Diogo joined Eli Lilly in 2021 as Chief Information and Digital Officer. He previously served in senior technology leadership roles at Apple, where he led global information systems and technology initiatives. Earlier in his career, he was a Partner at McKinsey & Company. He holds undergraduate and graduate degrees from Stanford University.

__________________________________________________________________________________

Daniel M. Skovronsky, MD, PhD

Chief Scientific Officer & Executive Vice President

Daniel has been with Eli Lilly since 2018 and serves as Chief Scientific Officer. He founded Avid Radiopharmaceuticals and previously served as its Chief Executive Officer prior to its acquisition by Lilly. He has held multiple scientific and leadership roles within Lilly’s research organization. He holds a medical degree and doctorate from the University of Pennsylvania and an undergraduate degree from Yale University.

__________________________________________________________________________________

Carole Ho, MD

Executive Vice President & President, Lilly Neuroscience

Carole joined Eli Lilly in 2025 as Executive Vice President and President of Lilly Neuroscience. She previously held senior leadership roles at Denali Therapeutics and Genentech, focusing on neurology and oncology development. Earlier in her career, she held medical and clinical leadership positions across major biotechnology companies. She earned her undergraduate degree from Harvard College and her medical degree from Weill Cornell Medicine.

__________________________________________________________________________________

Jacob S. van Naarden

President, Lilly Oncology & Executive Vice President

Jacob joined Eli Lilly in 2024 as President of Lilly Oncology. He previously served as Chief Executive Officer of Loxo Oncology and held investment and healthcare leadership roles at Goldman Sachs and Aisling Capital. He brings experience in oncology strategy, corporate development, and capital markets. He completed his undergraduate studies at Princeton University.

__________________________________________________________________________________

Anat Hakim

Secretary, Executive Vice President & General Counsel

Anat joined Eli Lilly in 2020 as Executive Vice President and General Counsel. She previously held senior legal leadership roles at Abbott Laboratories, including Divisional Vice President and Associate General Counsel. Earlier in her career, she practiced law at Latham & Watkins LLP. She holds an undergraduate degree from the University of Wisconsin and a law degree from Harvard Law School.

__________________________________________________________________________________

Find LLY's 10 Year Financial Statements below.

LLY Financial Statements.xlsx

Download XLSX • 34KB